Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from Analysts

Key Points

• Replimune Group, Inc. has received an average analyst rating of "Hold", with two analysts recommending a sell, six a hold, and two a buy, resulting in a 12-month price target of $6.50.
• Recent insider activity includes CFO Emily Luisa Hill selling 9,154 shares at $5.37 per share, a 6.38% decrease in her ownership of the company.
• Replimune Group reported a loss of ($0.95) EPS compared to an expected loss of ($0.83), indicating a miss against analysts' consensus estimates for the quarter.

Shares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have earned an average recommendation of "Hold" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $6.50.

Several equities analysts recently weighed in on REPL shares. HC Wainwright reiterated a "neutral" rating on shares of Replimune Group in a research report on Monday, September 8th. Wedbush reiterated a "neutral" rating and set a $4.00 price objective (down from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Jefferies Financial Group decreased their target price on shares of Replimune Group from $31.00 to $6.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Piper Sandler lowered shares of Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 price target for the company. in a research report on Tuesday, July 22nd. Finally, JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of Replimune Group in a research note on Friday, September 19th.

Insider Buying and Selling at Replimune Group

In related news, CFO Emily Luisa Hill sold 9,154 shares of Replimune Group stock in a transaction on Friday, August 15th. The stock was sold at an average price of $5.37, for a total value of $49,156.98. Following the transaction, the chief financial officer owned 134,368 shares in the company, valued at approximately $721,556.16. This trade represents a 6.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.20% of the company's stock.

Hedge Funds Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently modified their holdings of the company. Nuveen LLC acquired a new position in shares of Replimune Group during the first quarter worth about $6,546,000. Nan Fung Trinity HK Ltd. purchased a new stake in shares of Replimune Group during the 2nd quarter valued at about $4,325,000. Exome Asset Management LLC lifted its position in Replimune Group by 438.6% during the 1st quarter. Exome Asset Management LLC now owns 294,846 shares of the company's stock worth $2,875,000 after acquiring an additional 240,108 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Replimune Group by 6.6% in the 1st quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company's stock worth $37,372,000 after acquiring an additional 237,185 shares during the period. Finally, Invesco Ltd. grew its position in Replimune Group by 266.3% in the first quarter. Invesco Ltd. now owns 322,343 shares of the company's stock valued at $3,143,000 after acquiring an additional 234,337 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Stock Performance

NASDAQ:REPL opened at $4.65 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.94 and a quick ratio of 6.94. The firm has a market cap of $362.98 million, a PE ratio of -1.44 and a beta of 0.42. The firm has a 50 day simple moving average of $5.23 and a 200-day simple moving average of $7.74. Replimune Group has a 1-year low of $2.68 and a 1-year high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). On average, equities analysts expect that Replimune Group will post -2.97 EPS for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.